Follow us:

Microsoft Pri0

Welcome to Microsoft Pri0: That's Microspeak for top priority, and that's the news and observations you'll find here from Seattle Times technology reporter Matt Day.

July 3, 2007 at 10:13 AM

Dendreon gets boost from scientific journal

Dendreon shares jumped nearly 14 percent to a high of $8.24 early Tuesday, boosted by a scientific article that cast positive light on its flagship anti-prostate cancer therapy, Provenge.

The stock’s price and volume came down in later trading, but as of 1 p.m. Eastern time shares traded at $7.66, or 6 percent above Monday’s close.

The article — from a journal published by the American Association of Cancer Research — says biotechnology therapies that spur the immune system to fight cancer help extend the survival of patients in clinical trials:

Evidence is emerging from several studies in which patient cohorts who first receive a cancer vaccine (as contrasted with control cohorts) benefit clinically from subsequent therapies.

Seattle-based Dendreon expected federal regulators to approve Provenge earlier in the year, but in May the U.S. Food and Drug Administration requested more data, sending the stock into a downward spin. The FDA’s decision has generated controversy among investors and biotechnology activists.

The article is “sort of validation of the technology, which is good for everyone involved,” said Dendreon spokeswoman Monique Greer.

This is the second time in less than 10 days that Dendreon gets a marketplace jolt. Last week, shares jumped 10 percent after an analyst said that the company was ripe for a lucrative foreign partnership.

Comments | More in Biotechnology

COMMENTS

No personal attacks or insults, no hate speech, no profanity. Please keep the conversation civil and help us moderate this thread by reporting any abuse. See our Commenting FAQ.



The opinions expressed in reader comments are those of the author only, and do not reflect the opinions of The Seattle Times.


The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►
The Seattle Times

To keep reading, you need a subscription upgrade.

We hope you have enjoyed your complimentary access. For unlimited seattletimes.com access, please upgrade your digital subscription.

Call customer service at 1.800.542.0820 for assistance with your upgrade or questions about your subscriber status.

The Seattle Times

To keep reading, you need a subscription.

We hope you have enjoyed your complimentary access. Subscribe now for unlimited access!

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Activate Subscriber Account ►